ArticleInternational journal of molecular sciences2013
The yin-yang of DNA damage response: roles in tumorigenesis and cellular senescence.
Article in International journal of molecular sciences, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed.
- Aging and cancer: current understandings and future perspectives.Signal transduction and targeted therapy · 2026Review
- Comparable Efficacy of Chitosan/miR-200b-3p and Lipofectamine/miR-200b-3p Delivered by Pluronic F127 Hydrogel to Facilitate Diabetic Wound Healing.International journal of nanomedicine · 2026Article
- Melatonin Prevents Tumor Growth: The Role of Genes Controlling the Circadian Clock, the Cell Cycle, and Angiogenesis.Journal of pineal research · 2025Article
- Unraveling the nexus between cellular senescence and malignant transformation: a paradigm shift in cancer research.Cancer biology & medicine · 2024Article
- Chk2 deletion rescues Bmi1 deficiency-induced mandibular osteoporosis by blocking DNA damage response pathway.American journal of translational research · 2023Article
- Human papillomavirus targets the YAP1-LATS2 feedback loop to drive cervical cancer development.Oncogene · 2022Article
- Aberrant expression of the UPF1 RNA surveillance gene disturbs keratinocyte homeostasis by stabilizing AREG.International journal of molecular medicine · 2020Article
- Crizotinib and PARP inhibitors act synergistically by triggering apoptosis in high-grade serous ovarian cancer.Oncotarget · 2019Article
- Imaging the DNA damage response with PET and SPECT.European journal of nuclear medicine and molecular imaging · 2017Review
- Potential survival markers in cancer patients undergoing chemotherapy.Clinical and experimental medicine · 2015Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Senescent cells are relatively stable, lacking proliferation capacity yet retaining metabolic activity. In contrast, cancer cells are rather invasive and devastating, with uncontrolled proliferative capacity and resistance to cell death signals. Although tumorigenesis and cellular senescence are seemingly opposite pathological events, they are actually driven by a unified mechanism: DNA damage. Integrity of the DNA damage response (DDR) network can impose a tumorigenesis barrier by navigating abnormal cells to cellular senescence. Compromise of DDR, possibly due to the inactivation of DDR components, may prevent cellular senescence but at the expense of tumor formation. Here we provide an overview of the fundamental role of DDR in tumorigenesis and cellular senescence, under the light of the Yin-Yang concept of Chinese philosophy. Emphasis is placed on discussing DDR outcome in the light of in vivo models. This information is critical as it can help make better decisions for clinical treatments of cancer patients.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.